Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 in Recurrent Metastatic Nasopharyngeal Carcinoma
NCT05126719Phase 2Active, not recruiting
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of becotatug vedotin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Lepu Biopharma Co., Ltd. Primary endpoint: Objective Response Rate by Independent Review Committee up to 24 months. Started Apr 2023; status: active, not recruiting.
02
Drugs
becotatug vedotin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05126719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126719.